{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-018249","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.407456+00:00","generated_at":"2026-06-01T08:44:34.100853+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monopar CFO Kim Tsuchimoto retiring; Karthik Radhakrishnan appointed successor","bullets":["CFO Kim Tsuchimoto retires effective June 30, 2024 after 35+ years; remains on Board.","Karthik Radhakrishnan appointed CFO, principal accounting and financial officer effective July 1, 2024.","Radhakrishnan receives $384,800 annual salary, 35% target bonus, and options for 125,000 shares vesting over 4 years.","Radhakrishnan has over 20 years experience; previously CFO of Opexa Therapeutics, founder of Titania Partners."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-018249","json":"https://secwatch.observer/filing/0001437749-24-018249.json","markdown":"https://secwatch.observer/filing/0001437749-24-018249.md","text":"https://secwatch.observer/filing/0001437749-24-018249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924018249/0001437749-24-018249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924018249/mnpr20240523c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:44:34.100853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c6fd42acd","claim":"Kim R. Tsuchimoto departed as Chief Financial Officer at Monopar Therapeutics.","evidence_excerpt":"Effective June 30, 2024, after a career spanning more than 35 years, Kim R. Tsuchimoto, the Chief Financial Officer of Monopar Therapeutics Inc. (“Monopar” or the “Company”), will be retiring.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924018249/0001437749-24-018249-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retiring"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"6b625e2995","claim":"Karthik Radhakrishnan was appointed as Chief Financial Officer at Monopar Therapeutics.","evidence_excerpt":"On May 23, 2024, the Company’s Board of Directors appointed, Karthik Radhakrishnan, age 53, to succeed Ms. Tsuchimoto as Monopar’s Chief Financial Officer, principal accounting officer and principal financial officer effective July 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924018249/0001437749-24-018249-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}